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Abstract 
Background and Aims 
Numerous studies have established that mortality risk in IBD patients is higher than the 
general population, but the causes of death have seldom been examined. We aimed to 
describe causes of death in IBD. 
Methods 
A matched cohort study using UK general practice data from Clinical Practice Research 
Datalink linked to death registration records. We described the distribution of causes of death 
among IBD patients by age at death and time since IBD diagnosis. We estimated age-specific 
mortality rates and hazard ratios of death in multivariable Cox proportional hazards models. 
Results 
20,293 IBD patients were matched to 83,261 non-IBD patients. The mortality rate was 40% 
higher in IBD patients (2005 deaths) than in non-IBD patients (6024 deaths) (adjusted overall 
hazard ratio = 1.4, 95% CI = 1.4—1.5), with greater risk of death in Crohn’s disease (hazard 
ratio = 1.6, 1.5—1.7) than in ulcerative colitis (1.3, 1.3—1.4). Causes attributable to IBD 
constituted 3.7% of all deaths in ulcerative colitis and 8.3% in Crohn’s disease. Among IBD 
patients, death was less likely to be due to circulatory, respiratory or neoplastic diseases than 
non-IBD patients. In both IBD and non-IBD patients all these causes became more clinically 
important with advancing age, with the commonest neoplastic cause of death being lung cancer, 
rather than gastrointestinal cancers.  
Conclusion 
IBD patients have an additional risk of death. Most IBD patients die of circulatory or 
respiratory causes, and the contribution to mortality from long-term complications of IBD are 
clinically less important. 
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Introduction 
Inflammatory bowel diseases (IBD) are of increasing importance at the population level, both 
because of their rising incidence 1 and the increasing medical costs of managing the significant 
morbidity they cause 2. They are also of importance because of their associated additional 
mortality.   
More than a decade ago we published mortality data from the United Kingdom (UK), based on 
an analysis of records from 16,550 IBD patients with 1,047 deaths and 82,917 matched controls 
with 3,758 deaths from the Clinical Practice Research Datalink (CPRD, then known as General 
Practice Research Database GPRD) 3. We found IBD to be associated with a 54% increase in 
mortality; and the increase was higher in Crohn’s disease (CD) (hazard ratio (HR):1.73, (95% 
confidence interval (CI): 1.54-1.96), than in ulcerative colitis (UC) (HR:1.44; 95% CI: 1.31-
1.58).  Since then other studies have found lower mortality rates. A large population-based 
study 4 from Denmark has shown that CD patients had a 50% greater mortality and UC patients 
a 10% greater mortality than the general population. A recent meta-analysis5 has shown an 
excess mortality of 19% and 38% in UC and CD patients respectively. It is clear from these 
studies taken together however that IBD is associated with a clinically important increase in 
mortality in many population. 
Far less clear are the causes of death and how they vary over time. A recent linkage of CPRD 
to official records of cause of death, as well as the passage of time allow us to address both of 
these questions.  
 
 
 
5 
 
Methods 
Data source  
The CPRD is the world's largest database of anonymised, longitudinal primary care medical 
records. It contains over 13 million active patient records, drawn from approximately 650 
primary care practices across the UK since 1987, covering 5–10% of the UK population. 
Within this dataset about 50% of practices have agreed that their data be linked to other national 
datasets, including death records from the Office for National Statistics. There is good evidence 
that CPRD is representative of the UK population in terms of age and sex6, and that the levels 
of morbidity shown within the data are representative of those seen within the UK IBD 
population7. 
Subjects and data extraction 
In the UK, general practitioners would not themselves diagnose and manage IBD. Patients 
presenting with relevant symptoms are referred by their general practitioners to 
gastroenterologists for further investigations and diagnosis. A diagnosis of IBD in CPRD 
therefore represents a communication to primary care of a diagnosis confirmed in secondary 
care. Patients with diagnostic codes for inflammatory bowel disease (IBD) were identified from 
linked CPRD practices only,  using records between January 1987 and January 2011, and were 
individually matched  by primary care practice, sex and date of birth (within one year) to up to 
five subjects without any records of IBD diagnosis to create a study cohort. The index date for 
each IBD patient, defined as the later of the date entering CPRD or the date of the earliest 
record of an IBD diagnosis, was constrained to fall between the dates entering and leaving 
CPRD in the matched non-IBD patients to ensure some overlap of observation time between 
the matched pairs.  
From these records we extracted diagnosis of IBD classified as UC, CD (defined as patient 
with either CD or UC codes but not both in their history diagnosis) or unclassified (defined a 
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patients with both UC and CD in their history diagnosis code). We also extracted for each 
subject age, body mass index (based on average lifetime body mass index records) and smoking 
status (highest recorded level of, from the highest level to the lowest, “current”, “ex-smoker”, 
“non-smoker or “unknown”).  
We obtained from the Office for National Statistics linked records of deaths occurring between 
1st January 1998 and 10th January 2012. From these we extracted date and cause of death. We 
only considered “the underlying cause of death” which is considered to be the cause which 
“initiated the sequence of events leading directly to death and prevention of which will result 
in the greatest health gain from a public health point of view”8. 
Statistical analysis 
Starting follow up from the later of 1/1/98 and the index date, we estimated the age-specific 
mortality rate for IBD patients and their matched non-IBD patients. Estimates of HR of death 
among IBD patients relative to non-IBD patients were adjusted for age at diagnosis, body mass 
index category and tobacco use status in Cox proportional hazards models.  
We examined the pattern of mortality among patients with CD or UC by classifying the 
underlying cause of death into one of the following groups: gastrointestinal, circulatory and 
respiratory, neoplastic, haematological, infective, and other specified causes. We also 
described the distribution of causes of death among IBD patients by age at death and time since 
IBD diagnosis. 
Ethics approval 
This project is covered under the ethical approval granted for studies in CPRD and received 
regulatory approval from the Independent Scientific Advisory Committee for MHRA database 
research (protocol number 10-147). 
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Results 
We identified 20,293 IBD patients from CPRD consultations records, who were matched to 
83,261 non-IBD patients (Table 1). Patients with CD were younger (mean age at diagnosis 42.4 
years) than patients with UC (49.3 years) or non-IBD patients (45.5 years). UC patients were 
more likely to be male (49.0%) than CD (43.7%) and non-IBD patients (46.5%).  CD patients 
were more likely to be underweight with 5.0% of patients having a recorded body-mass index 
(BMI) of under 18.5, compared to only 2.7% of UC and 2.8% of non-IBD patients. Most IBD 
patients were not current smokers (40.4% in CD, 49.3% in UC) reflecting the general public 
trend (45.9% in non-IBD). The prevalence of current smokers in the CD cohort was much 
higher than in the UC cohort (37.4%, versus 22.2%). 
The overall mortality rate was 14.3 per 1,000 person-years among IBD patients (95% CI: 13.7-
14.9) and 11.1 per 1,000 person-years in non-IBD patients (95% CI: 10.8-11.3), implying the 
mortality rate in IBD patients was around 40% higher than in non-IBD patients (HR: 1.4, 95% 
CI: 1.4-1.5) (Table 2). The age-specific mortality rates increased with age in both IBD and non-
IBD patients, though this increase was steeper in IBD patients such that the absolute difference 
in mortality rates was greater in the elderly. For example, in CD patients aged under 20 years 
the absolute mortality rate was 0.8 per 1,000 person-years (compared to 0.1 per 1,000 person-
years in non-IBD patients), and in UC patients of the same age the absolute mortality rate was 
1.9 per 1,000 person-years (compared to 0.2 per 1,000 person-years in non-IBD patients). In 
contrast the mortality rate in those over 80 years of age was 190.0 per 1,000 person-years for 
CD patients and 182.3 per 1,000 for those with UC. Again these rates were higher than in 
matched non-IBD patients with rates of 133.0 and 126.3 per 1000 person years respectively. 
Unlike the absolute differences in mortality, the age-specific hazard ratios for mortality in IBD 
patients relative to non-IBD patients were large in young patients but the ratios decreased with 
age such that the adjusted HR for mortality rate in IBD was highest in patients diagnosed before 
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the age of 20 years (CD, 8.8, 95% CI: 0.8-97.5 and UC, 13.6, 95% CI: 1.4-129.9) These 
contrasting trends are illustrated in Table 2 and Figures 1,2 and 3.  
Tables 3, 4 and 5 set out the causes of death recorded by age at death for IBD patients and 
controls (tables 3 and 4), and by time since diagnosis in IBD patients (table 5). 
The most common causes of death in IBD patients were circulatory or respiratory diseases 
(41.3% in CD, 42.9% in UC), followed by neoplastic causes (23.6% in CD and 26.2% in UC) 
(Table 3). The commonest neoplastic cause of death in both CD and UC was lung cancer, 
contributing to 3.2% of deaths in CD and 5.1% in UC. In both types of IBD, lower GI 
malignancy was the next commonest neoplastic cause (3.9% and 4.3% respectively), followed 
by pancreatic and hepato-biliary tumours (1.9% and 2.7%). Inflammatory bowel diseases and 
their complications together accounted for 8.8% of the underlying cause of death among CD 
patients and 4.1% among UC patients. Infections, leukaemias and lymphomas combined 
accounted for a small proportion of overall deaths (3.4% in CD and 3.5% in UC). 
The proportion of the underlying cause of death in CD patients accounted for by circulatory 
and respiratory disease increased with age from 17.7% among 20–40 year-olds to 46.1% among 
over 80 year-olds (Table 3). A similar pattern was also observed in UC patients. The 
importance of gastrointestinal diseases (other than malignancy) as a cause of death decreased 
from 50% among under 20 year-olds to 12% among over 80 year-olds in CD and from 50% to 
8.2% in UC. The proportion of deaths attributed to a neoplastic cause fell steadily from almost 
50% among 20–40 year-olds to 18.7% among over 80 year-olds in UC patients. In CD patients 
and non-IBD patients, no neoplastic causes of death were identified early in life but these 
increased to 29.1% among 60-80 years-old in CD and 42.7% among 40-60 years-old non-IBD 
patients, (Table 4). 
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The proportion of death with gastrointestinal diseases as an underlying cause similarly declined 
with a longer history of UC (7.8% in patients with a history of over 20 years compared to 
14.8% in the first five years after diagnosis)(Table 5). The proportion of gastrointestinal deaths 
also declined in CD, though the decline in deaths directly due to this disease was less marked, 
and they remained at a higher proportion than for UC patients throughout its course (in total 
4.1% of deaths in UC patients were due to  IBD and its complications compared to 8.8% in 
CD).  
In CD, the proportion of deaths attributed to neoplasia increased from 20.4% for deaths within 
5 years of a diagnosis to 30.2% in patients with over 20 years of disease. This increase was 
predominantly driven by an increase in hepatobiliary (0.6% to 2.5%) and lung cancers (1.2% 
to 4.3%). Deaths due to lower gastrointestinal cancer decreased from 6.2% to 4.3% in the same 
time frames. 
In UC, the proportion of deaths attributed to neoplasia decreased from 29.2% for deaths within 
5 years of a diagnosis to 24.6% in patients with over 20 years of disease. This decline was 
predominantly driven by a decrease in deaths due to lung cancer (8.2% to 3.2%) within the 
same time frames. These were counterbalanced by an increase in deaths due to lower 
gastrointestinal and hepatobiliary cancers (3.1% and 1.7% with 5 years of diagnosis to 5.6% 
and 3.6% after 20 years of diagnosis respectively).  
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Discussion 
We have described the pattern of 2,005 deaths in a UK cohort of 20,293 patients with IBD 
which, is among the largest such cohorts with linkage to data from the official records of death. 
We have previously published mortality data on 16,550 IBD patients using CPRD records more 
than a decade ago 3 providing us an excellent opportunity to witness the changes in IBD-related 
mortality within the UK over a period in which the use of immunosuppressive and biological 
therapy is increasing 9,10. A diagnosis of IBD was associated with a roughly 40% increase in 
the overall risk of mortality, (60% in CD and 30% in UC) which is only marginally lower than 
our previously published data. 
Before further examining or interpreting our results it is necessary to consider their validity. 
This study has provided power to examine the trends and variations in causes of death by IBD 
type, age and duration.  Furthermore it utilises data which provide for correction of the 
confounding effects of BMI and smoking which are both associated with IBD, as well as being 
important predictors of death independent of IBD. There are some limitations to this study 
however. Firstly as with all studies based on electronic records there is potential for error in 
coding. The two gravest concerns in this regard would be for the coding of IBD and of death. 
Though we cannot individually validate each diagnosis of IBD, we are able to be confident as 
to the validity of this coding since it has previously been validated in these data 11. This 
validation however confirms only that those coded as having IBD are highly likely to have it, 
and it remains possible that a proportion of cases prevalent when joining CPRD will remain 
unrecorded if quiescent throughout their record. Based upon the previous validation of duration 
over which prevalent cases can be expected to be recorded 12 we think it will be unlikely for 
this to be a major issue. Though omission of such cases may bias our estimation of the pattern 
of deaths associated with IBD towards that seen in more active cases this is likely to be a far 
smaller issue in this population based study than in many disease cohorts collected in secondary 
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care. With regard to death and its causes, we can be highly confident that registration of the 
fact of death is valid and complete given the source of such data is the official registrations of 
death originally from the Local Registration Service and the General Register Office. However 
it is well recognised that the coding of cause of death is prone to error 13. Short of post mortem 
examination and full case note review (which are not available to us), the data we have used is 
the best possible and since it is compiled for administrative purposes rather than for this study, 
is unlikely to be greatly biased. 
It is interesting to compare our results with those previously published. The overall pattern of 
our results is in agreement with our own previous findings when we reported a proportionate 
increase in mortality of 54% in all IBD patients 3, the magnitude of the relative risk now 
reported is only slightly smaller despite the quite marked changes in therapy over this period 
9,10. Other studies have identified varying increased risks of death among IBD patients 3,4,14-18 
while other studies found no increase 19-23. A recent meta-analysis of 35 studies in IBD 
concluded that the standardised mortality ratios in UC and CD were 1.19 (95% CI, 1.06-1.35) 
and 1.38 (95% CI, 1.23-1.55), respectively5. Our results are not too dissimilar to these. 
We also are for the most part in agreement with previous studies regarding the change in 
relative mortality with age. Though one Scandinavian population-based study suggested a 
significant increased mortality in only female CD patients diagnosed in their third or fifth 
decade of life 15, in a subsequent larger study by the same group, the highest relative risk of 
death was in CD patients diagnosed before the age of 20 (adjusted HR: 1.62; 95% CI, 1.25–
2.09) 4. The same group similarly found in population-based studies of UC, 4,17 that UC-related 
mortality was increased 2-fold in young people diagnosed with UC before the age of 20. Our 
own findings that the highest relative risk of mortality was observed in patients diagnosed 
before the age of 20 for both UC and CD (adjusted age-specific HR of 13.6 (95% CI: 1.4-
129.9) and 8.8 (95% CI: 0.8-97.5) respectively) before declining in older age groups to between 
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1.0 and 2.0 accords with this. A population-based study from Manitoba16 had slightly different 
findings with the highest relative mortality observed in CD patients between the ages of 30-49.  
This study though reported this stratification only for incident cases of IBD, and did not have 
a separate category for those under 20. Their <30 category had the highest relative mortality in 
UC though the excess (HR 1.15 (95% CI: 0.66-2.01)) was not significant. 
One area in which we have been able to add information not immediately comparable to 
previous studies is in the variations in cause of death over time. It is well recognised that 
patients with IBD may be at increased risk of death from a number of causes 4,14,16,20,24, and 
that the commonest causes of their deaths are cardiovascular disease and neoplasia just as in 
the general population 4,14,16. On these points we agree. What we have been able to add is insight 
into how this changes with age as well as with time from diagnosis. Regarding time from 
diagnosis, a small number of studies have already provided some insight, showing as we do 
that gastrointestinal causes are prominent early in the course of IBD and decline in importance 
with time  late 4,14. These studies though report the declining relative risk, where we have given 
the proportion of deaths attributed to a particular cause. This shows that in the first 5 years after 
a diagnosis of CD, 11.7% of deaths in this subgroup were directly attributable to CD or its 
complications and all gastrointestinal causes combined (except neoplasms) were the underlying 
cause in 20.4% of deaths. In UC patients, 7.6% of deaths in the first five years of diagnosis 
were directly attributable to UC or its complications and all gastrointestinal causes (excluding 
neoplasms) were responsible for 14.8% of deaths. The importance of gastrointestinal diseases 
as the underlying cause of death declines relative to other causes such that in patients with over 
20 years of IBD history, 11.1% of deaths in those with CD and 7.8% in UC were of GI cause. 
Overall, 15.0% of deaths in CD are due to GI causes and 8.3% directly to CD, and the 
comparable figures for UC are 10.0% and 3.7% respectively. We have also shown that the 
contribution of GI deaths declines as a proportion with age from 50% in the under 20s to about 
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12% in the over 80s for both diseases. Trends in other causes of death as a proportion must of 
course compensate for these variations, and we show that circulatory and respiratory deaths 
gradually rise with age from under 20% in those under age 40 to about 46% over the age of 80. 
Interestingly though neoplasia is classically a disease of the old, the proportion of deaths due 
to it in UC falls with age (though not with time since diagnosis). There were 19 deaths from 
lower gastrointestinal cancers in the first 5 years after the diagnosis of IBD, perhaps in keeping 
with the high hazard for death from this cause previously reported in the early years 4. What 
may perhaps surprise gastroenterologists more is that despite the recognised high risk of 
developing lower gastrointestinal cancers, and the low level of smoking, UC patients remained 
more likely to die of lung cancer (5.1%) than of colorectal cancers (4.4%).  
When comparing our current results to those from the time period we previously studied 3, the 
well-known changes in management of IBD have not been associated with a change in the risk 
of death. We are unfortunately unable to comment on changes in cause of death as we did not 
previously have this data. It is reassuring to note however that notwithstanding the well-
recognised risks of immunosuppression and biologics and their added risk of infection 25 and 
haematological malignancy 26, they were not associated with an additional risk of death among 
IBD patients compared to non-IBD patients and remain uncommon causes of death in IBD 
patients. 
In summary, we have shown that IBD continues to be associated with an increased risk of 
death in the UK, that this is at least partially explained by deaths caused by IBD itself and its 
complications, but that most patients with IBD will die of unrelated causes in a pattern much 
akin to that in the general population.  
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Table 1: Characteristics of patients with and without inflammatory bowel disease recorded in CPRD. 
 
    Crohn's disease Ulcerative colitis All IBD patients combined Non-IBD patients 
 
 N = 6,599 N = 9,993 N = 20,293 N = 83,261 
    n % n % n % n % 
Male 2,885 43.7 4,900 49 9,465 46.6 38,708 46.5 
Mean age (years) 42.4 49.3 46 45.5 
Body mass index     
  
 
 
 0-18.5 333 5 265 2.7 748 3.7 2,300 2.8 
 18.5-
25.0 
2,876 43.6 3,926 39.3 8,316 41 30,632 36.8 
 25.0-
30.0 
1,590 24.1 2,945 29.5 5,561 27.4 22,507 27 
 30.0-
50.0 
806 12.2 1,417 14.2 2,783 13.7 12,358 14.8 
 Unknown 994 15.1 1,440 14.4 2,885 14.2 15,464 18.6 
Tobacco use     
  
 
 
 Current 2,469 37.4 2,214 22.2 5,804 28.6 26,191 31.5 
 Ex-
smoker 
1,116 17.7 2,431 24.3 4,364 21.5 12,736 15.3 
 Not 
current 
2,669 40.4 4,931 49.3 9,270 45.7 38,254 45.9 
  Unknown 295 4.5 417 4.2 855 4.2 6,080 7.3 
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Table 2: Mortality rates, by age at diagnosis, in patients with Crohn's disease and ulcerative colitis and their matched non-IBD patients. 
    IBD patients Matched non-IBD patients Hazard ratio 
Age at 
diagnosis 
(years) 
Deaths 
Follow-
up (p-y) 
Mortality 
rate 
95% CI Deaths 
Follow-up 
(p-y) 
Mortality 
rate 
95% CI 
Adjusted 
estimate 
95% CI 
(1,000 p-
y) 
(1,000 p-
y) 
Crohn's 
disease 
563 45,672.90 12.3 11.3 – 13.4 1,457 177,296.30 8.2 7.8 – 8.7 1.6 1.5 – 1.7 
 0-20 2 2,393.60 0.8 0.2 – 3.3 1 9,403.80 0.1 0 – 0.8 8.8 0.8 – 97.5 
 20-40 28 22,186.20 1.3 0.9 – 1.8 65 83,842.00 0.8 0.6 – 1 1.7 1.1 – 2.6 
 40-60 113 14,354.00 7.9 6.5 – 9.5 256 55,346.50 4.6 4.1 – 5.2 1.7 1.4 – 2.1 
 60-80 262 5,907.40 44.4 39.3 – 50.1 695 25,395.00 27.4 25.4 – 29.5 1.6 1.3 – 1.8 
 over 
80 
158 831.6 190 162.6 – 222 440 3,309.00 133 121.1 – 146 1.3 1.1 – 1.6 
Ulcerative 
colitis 
1,141 69,412.20 16.4 15.5 – 17.4 3,674 267,932.80 13.7 13.3 – 14.2 1.3 1.3 – 1.4 
 0-20 3 1,549.40 1.9 0.6 – 6 1 6,103.00 0.2 0 – 1.2 13.6 1.4 – 129.9 
 20-40 39 23,937.70 1.6 1.2 – 2.2 65 89,275.40 0.7 0.6 – 0.9 2.4 1.6 – 3.6 
 40-60 128 25,772.30 5 4.2 – 5.9 459 100,184.70 4.6 4.2 – 5 1.2 1 – 1.5 
 60-80 523 15,695.10 33.3 30.6 – 36.3 1,796 61,658.60 29.1 27.8 – 30.5 1.2 1.1 – 1.3 
 over 
80 
448 2,457.80 182.3 166.2 – 200 1,353 10,711.10 126.3 119.8 – 133.2 1.4 1.3 – 1.6 
All IBD 
patients 
2,005 140,554.5 14.3 13.7 – 14.9 6,024 544,761.70 11.1 10.8 – 11.3 1.4 1.4 – 1.5 
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Table 3: Distribution of the cause of death, by age at death, in patients with a diagnosis of Crohn's disease or ulcerative colitis in CPRD. 
 
Age at death 
0-20 
years 
20-40 
years 40-60 years 60-80 years 
over 80 
years TOTAL 
Cause of death n % n % n % n % n % n % 
Crohn's disease at diagnosis             
Gastrointestinal 1 50.0 4 23.5 17 19.8 36 15.7 28 12.0 86 15.1 
  IBD 1 50.0 1 5.9 8 9.3 20 8.7 17 7.3 47 8.3 
  complications of IBD 0 0.0 1 5.9 0 0.0 1 0.4 1 0.4 3 0.5 
  other 0 0.0 2 11.8 9 10.5 15 6.5 10 4.3 36 6.3 
Circulatory and respiratory 0 0.0 3 17.6 29 33.7 95 41.3 108 46.2 235 41.3 
  venous thromboembolism 0 0.0 1 5.9 1 1.2 2 0.9 3 1.3 7 1.2 
  stroke 0 0.0 0 0.0 2 2.3 18 7.8 23 9.8 43 7.6 
  other circulatory causes 0 0.0 2 11.8 18 20.9 46 20.0 44 18.8 110 19.3 
  all respiratory causes 0 0.0 0 0.0 8 9.3 29 12.6 38 16.2 75 13.2 
Neoplastic 0 0.0 2 11.8 24 27.9 67 29.1 41 17.5 134 23.6 
  upper gastrointestinal 0 0.0 1 5.9 0 0.0 5 2.2 2 0.9 8 1.4 
  lower gastrointestinal 0 0.0 1 5.9 4 4.7 12 5.2 5 2.1 22 3.9 
  liver, gall bladder and pancreas 0 0.0 0 0.0 2 2.3 6 2.6 3 1.3 11 1.9 
  lung 0 0.0 0 0.0 2 2.3 8 3.5 8 3.4 18 3.2 
  skin 0 0.0 0 0.0 0 0.0 1 0.4 1 0.4 2 0.4 
  uterine cervix 0 0.0 0 0.0 1 1.2 0 0.0 0 0.0 1 0.2 
  leukaemia and lymphoma 0 0.0 0 0.0 3 3.5 6 2.6 0 0.0 9 1.6 
  other 0 0.0 0 0.0 12 14.0 29 12.6 22 9.4 63 11.1 
Haematological disorders 0 0.0 0 0.0 1 1.2 0 0.0 1 0.4 2 0.4 
Infective 0 0.0 2 11.8 3 3.5 2 0.9 3 1.3 10 1.8 
Other specified causes 1 50.0 6 35.3 12 14.0 30 13.0 53 22.6 102 17.9 
 Sub-total for Crohn's disease 2 100.0 17 100.0 86 100.0 230 100.0 234 100.0 569 100.0 
18 
 
Ulcerative colitis at diagnosis           
 
 
Gastrointestinal 1 50.0 1 5.6 16 13.9 46 12.0 52 8.2 116 10.1 
  IBD 1 50.0 0 0.0 4 3.5 16 4.2 22 3.5 43 3.7 
  complications of IBD 0 0.0 0 0.0 0 0.0 4 1.0 1 0.2 5 0.4 
  other 0 0.0 1 5.6 12 10.4 26 6.8 29 4.6 68 5.9 
Circulatory and respiratory 0 0.0 4 22.2 29 25.2 165 43.1 297 46.8 495 42.9 
  venous thromboembolism 0 0.0 1 5.6 0 0.0 6 1.6 6 0.9 13 1.1 
  stroke 0 0.0 0 0.0 3 2.6 28 7.3 68 10.7 99 8.6 
  other circulatory causes 0 0.0 3 16.7 16 13.9 75 19.6 125 19.7 219 19.0 
  all respiratory causes 0 0.0 0 0.0 10 8.7 56 14.6 98 15.4 164 14.2 
Neoplastic 1 50.0 8 44.4 53 46.1 121 31.6 119 18.7 302 26.2 
  upper gastrointestinal 0 0.0 0 0.0 2 1.7 4 1.0 7 1.1 13 1.1 
  lower gastrointestinal 1 50.0 1 5.6 13 11.3 19 5.0 16 2.5 50 4.3 
  liver, gall bladder and pancreas 0 0.0 1 5.6 6 5.2 14 3.7 10 1.6 31 2.7 
  lung 0 0.0 0 0.0 6 5.2 29 7.6 24 3.8 59 5.1 
  skin 0 0.0 0 0.0 2 1.7 1 0.3 2 0.3 5 0.4 
  uterine cervix 0 0.0 0 0.0 1 0.9 1 0.3 2 0.3 4 0.3 
  leukaemia and lymphoma 0 0.0 3 16.7 3 2.6 7 1.8 12 1.9 25 2.2 
  other 0 0.0 3 16.7 20 17.4 46 12.0 46 7.2 115 10.0 
Haematological disorders 0 0.0 0 0.0 0 0.0 2 0.5 3 0.5 5 0.4 
Infective 0 0.0 0 0.0 1 0.9 5 1.3 9 1.4 15 1.3 
Other specified causes 0 0.0 5 27.8 16 13.9 44 11.5 155 24.4 220 19.1 
 
Sub-total for ulcerative 
colitis 2 100.0 18 100.0 115 100.0 383 100.0 635 100.0 1,153 100.0 
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Table 4: Distribution of the cause of death, by age at death, in patients without inflammatory bowel disease in CPRD. 
Age at death 0-20 years 20-40 years 40-60 years 60-80 years over 80 years TOTAL 
Cause of death n % n % n % n % n % n % 
Gastrointestinal 0 0.0 6 6.2 68 11.1 108 4.5 129 3.9 311 4.9 
 IBD 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 
 complications of IBD 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 
 other 0 0.0 6 6.2 68 11.1 108 4.5 129 3.9 311 4.9 
Circulatory and respiratory 1 33.3 18 18.6 157 25.7 1,037 43.5 1,798 54.4 3,011 47.0 
 venous thromboembolism 0 0.0 1 1.0 1 0.2 11 0.5 31 0.9 44 0.7 
 stroke 0 0.0 0 0.0 20 3.3 158 6.6 400 12.1 578 9.0 
 other circulatory causes 1 33.3 13 13.4 107 17.5 591 24.8 834 25.2 1,546 24.2 
 all respiratory causes 0 0.0 4 4.1 29 4.7 277 11.6 533 16.1 843 13.2 
Neoplastic 0 0.0 22 22.7 261 42.7 979 41.0 619 18.7 1,881 29.4 
 upper gastrointestinal 0 0.0 1 1.0 18 2.9 71 3.0 47 1.4 137 2.1 
 lower gastrointestinal 0 0.0 2 2.1 16 2.6 99 4.2 72 2.2 189 3.0 
 liver, gall bladder and pancreas 0 0.0 0 0.0 22 3.6 65 2.7 43 1.3 130 2.0 
 lung 0 0.0 1 1.0 38 6.2 246 10.3 115 3.5 400 6.2 
 skin 0 0.0 3 3.1 9 1.5 13 0.5 9 0.3 34 0.5 
 uterine cervix 0 0.0 2 2.1 4 0.7 5 0.2 1 0.0 12 0.2 
 leukaemia and lymphoma 0 0.0 1 1.0 15 2.5 80 3.4 37 1.1 133 2.1 
 other 0 0.0 12 12.4 139 22.7 400 16.8 295 8.9 846 13.2 
Haematological disorders 0 0.0 0 0.0 1 0.2 1 0.0 4 0.1 6 0.1 
Infective 0 0.0 0 0.0 8 1.3 17 0.7 33 1.0 58 0.9 
Other specified causes 2 66.7 51 52.6 116 19.0 243 10.2 722 21.8 1,134 17.7 
 All causes combined 3 100.0 97 100.0 611 100.0 2,385 100.0 3,305 100.0 6,401 100.0 
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Table 5: Distribution of the cause of death, by time since diagnosis, in patients with a diagnosis of Crohn's disease or ulcerative 
colitis in CPRD. 
              
Time since IBD diagnosis 0-5 years 5-10 years 10-15 years 15-20 years over 20 years TOTAL 
Cause of death n % n % n % n % n % n % 
Crohn's disease at diagnosis             
Gastrointestinal 33 20.4 15 13.8 11 13.3 8 15.7 18 11.1 85 15.0 
  IBD 18 11.1 8 7.3 6 7.2 5 9.8 10 6.2 47 8.3 
  complications of IBD 1 0.6 1 0.9 0 0.0 0 0.0 1 0.6 3 0.5 
  other 14 8.6 6 5.5 5 6.0 3 5.9 7 4.3 35 6.2 
Circulatory and respiratory 70 43.2 45 41.3 40 48.2 20 39.2 60 37.0 235 41.4 
  venous thromboembolism 2 1.2 2 1.8 2 2.4 0 0.0 1 0.6 7 1.2 
  stroke 12 7.4 5 4.6 12 14.5 3 5.9 11 6.8 43 7.6 
  other circulatory causes 31 19.1 25 22.9 17 20.5 11 21.6 26 16.0 110 19.4 
  all respiratory causes 25 15.4 13 11.9 9 10.8 6 11.8 22 13.6 75 13.2 
Neoplastic 33 20.4 25 22.9 11 13.3 15 29.4 49 30.2 133 23.5 
  upper gastrointestinal 1 0.6 2 1.8 2 2.4 1 2.0 2 1.2 8 1.4 
  lower gastrointestinal 10 6.2 4 3.7 0 0.0 1 2.0 7 4.3 22 3.9 
  liver, gall bladder and pancreas 1 0.6 1 0.9 2 2.4 3 5.9 4 2.5 11 1.9 
  lung 2 1.2 6 5.5 2 2.4 1 2.0 7 4.3 18 3.2 
  skin 0 0.0 0 0.0 0 0.0 0 0.0 2 1.2 2 0.4 
  uterine cervix 1 0.6 0 0.0 0 0.0 0 0.0 0 0.0 1 0.2 
  leukaemia and lymphoma 3 1.9 3 2.8 0 0.0 1 2.0 2 1.2 9 1.6 
  other 15 9.3 9 8.3 5 6.0 8 15.7 25 15.4 62 10.9 
Haematological disorders 1 0.6 0 0.0 0 0.0 1 2.0 0 0.0 2 0.4 
Infective 3 1.9 1 0.9 3 3.6 0 0.0 3 1.9 10 1.8 
Other specified causes 22 13.6 23 21.1 18 21.7 7 13.7 32 19.8 102 18.0 
 
Sub-total for Crohn's 
disease 162 100.0 109 100.0 83 100.0 51 100.0 162 100.0 567 100.0 
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Ulcerative colitis at diagnosis             
Gastrointestinal 43 14.8 27 14.5 7 4.3 6 6.3 32 7.8 115 10.0 
  IBD 20 6.9 6 3.2 4 2.5 2 2.1 10 2.4 42 3.7 
  complications of IBD 2 0.7 1 0.5 0 0.0 0 0.0 2 0.5 5 0.4 
  other 21 7.2 20 10.8 3 1.8 4 4.2 20 4.9 68 5.9 
Circulatory and respiratory 119 40.9 72 38.7 86 52.8 44 45.8 172 41.8 493 43.0 
  venous thromboembolism 2 0.7 1 0.5 5 3.1 0 0.0 5 1.2 13 1.1 
  stroke 27 9.3 12 6.5 13 8.0 9 9.4 38 9.2 99 8.6 
  other circulatory causes 48 16.5 35 18.8 43 26.4 21 21.9 71 17.3 218 19.0 
  all respiratory causes 42 14.4 24 12.9 25 15.3 14 14.6 58 14.1 163 14.2 
Neoplastic 85 29.2 53 28.5 40 24.5 22 22.9 101 24.6 301 26.2 
  upper gastrointestinal 2 0.7 1 0.5 2 1.2 0 0.0 8 1.9 13 1.1 
  lower gastrointestinal 9 3.1 7 3.8 4 2.5 7 7.3 23 5.6 50 4.4 
  liver, gall bladder and pancreas 5 1.7 6 3.2 5 3.1 0 0.0 15 3.6 31 2.7 
  lung 24 8.2 9 4.8 6 3.7 6 6.3 13 3.2 58 5.1 
  skin 4 1.4 0 0.0 1 0.6 0 0.0 0 0.0 5 0.4 
  uterine cervix 1 0.3 1 0.5 0 0.0 1 1.0 1 0.2 4 0.3 
  leukaemia and lymphoma 5 1.7 5 2.7 7 4.3 4 4.2 4 1.0 25 2.2 
  other 35 12.0 24 12.9 15 9.2 4 4.2 37 9.0 115 10.0 
Haematological disorders 2 0.7 0 0.0 0 0.0 0 0.0 3 0.7 5 0.4 
Infective 3 1.0 4 2.2 2 1.2 1 1.0 4 1.0 14 1.2 
Other specified causes 39 13.4 30 16.1 28 17.2 23 24.0 99 24.1 219 19.1 
 
Sub-total for ulcerative 
colitis 291 100.0 186 100.0 163 100.0 96 100.0 411 100.0 1,147 100.0 
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Table captions 
 
Figures 
 
Figure 1 
Mortality rates (number of deaths per 1000 person-years) in Crohn's disease patients and their 
matched non-IBD patients, by age at diagnosis. 
 
Grey bars: mortality rate in non-IBD patients, white bars: additional mortality rate in Crohn's 
disease patients. Total height (grey and white parts) of each bar is the mortality rate in Crohn's 
disease patients. 
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Figure 2 
Mortality rates (number of deaths per 1000 person-years) in ulcerative colitis patients and their 
matched non-IBD patients, by age at diagnosis. 
 
Grey bars: mortality rate in non-IBD patients, white bars: additional mortality rate in ulcerative 
colitis patients. Total height (grey and white parts) of each bar is the mortality rate in ulcerative 
colitis patients. 
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Figure 3 
Age-related pattern in the estimated hazard ratios of death relative to matched non-IBD 
patients, adjusted for age at diagnosis, body mass index category and tobacco use status. 
 
Solid circles: Hazard ratios in Crohn's disease patients, hollow circles: hazard ratios in 
ulcerative colitis patients. Vertical lines: 95% confidence intervals of hazard ratios. 
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